[Form 4] Channel Therapeutics Corporation Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
10,000 shares exercised/converted
Mixed
4 txns
Insider
Francis Knuettel II
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Series A Convertible Preferred Stock | 10,000 | $0.00 | -- |
| Conversion | Series A Convertible Preferred Stock | 10,000 | $0.00 | -- |
| Conversion | Common Stock | 10,000 | $10.00 | $100K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Series A Convertible Preferred Stock — 10,000 shares (Indirect, See footnote);
Common Stock — 10,000 shares (Indirect, By Camden Capital LLC)
Footnotes (1)
- The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. Acquired in connection with cancellation of promissory note.
